UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
UNITY Biotechnology [NASDAQ: UBX] has scheduled a corporate update and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UNITY Biotechnology [NASDAQ: UBX] has scheduled a corporate update and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM ET. The company focuses on developing therapeutics to address diseases of aging, particularly targeting age-related ophthalmologic and neurologic diseases by eliminating or modulating senescent cells. The presentation will be accessible via webcast and can also be found on their website under the 'Investors and Media' section.
Details
News Market Reaction – UBX
The recorded move for UBX in the trading session of this news was +10.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 11:20 AM ET.
The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.”
About UNITY
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.